COVID-19 Response + Recovery Cross-Functional Team Update

2.1.2021

Updated 2.1.21

Table of Contents

1. **Overview (Tommy Gonzalez)**
2. **CFT Operations (Chief Mario D'Agostino)**
3. **City Attorney Overview (Karla Nieman)**
   a) Governor Abbott renews COVID-19 Disaster Declaration
   b) Emergency Ordinances
   c) City Attorney's Office COVID-19 Support
4. **Team Lead Reports:**
   1. **Health Focus (Hector Ocaranza, M.D.)**
   a) Community Task Force Recommendations Update (Dionne Mack)
   2. **Vaccination Update (Angela Mora)**

1. Overview

Tommy Gonzalez

2. CFT Operations Overview

Chief Mario D’Agostino

3. CAO Overview

- Governor Abbott renews COVID-19 Disaster Declaration
- Emergency Ordinances
- City Attorney's Office COVID-19 Support
- Legal Monitoring

Karla Nieman

Governor Abbott's Disaster Declarations

MARCH 13

Governor Abbott issues Disaster Declaration

→

JAN. 5

Governor Abbott renewed COVID-19 Disaster Declaration

→

FEB. 4*

Governor Abbott renewed COVID-19 Disaster Declaration

*Anticipate Governor Abbott will renew his Disaster Declaration between Feb. 4th – 7th.

Emergency Ordinances

Ordinance	Adoption Date	Last Re-enactment	Expires
Disaster Declaration Ord. No. 019035	3/17/2020	1/5/2021	2/4/2021
Emergency Measures Ord. No. 019036	3/17/2020	1/5/2021	2/4/2021
Public Right of Way Ord. No. 019091	8/31/2020	1/5/2021	2/4/2021

City Attorney's Office COVID-19 Support

Upcoming February Hearings on COVID-19 Citations

Arraignment Hearings	Pre-Trials	Trials
53	5	19
4 waived		

The City Attorney's Office continues to provide enforcement training on local, state and federal COVID-19 guidelines to the City's Fire and Police Departments.

Legal Monitoring

- Judicial Orders
- Eviction Orders
- Testing & Vaccine Employee Initiatives
- Federal Funding Requirements
- American Rescue Plan and impact on FFCRA

4. Team Lead Reports

1. Health Focus

Hector I. Ocaranza, M.D.

COVID-19
in our community

COVID-19 Snapshot

- Positive cases are now stable with day-to-day variation
- New cases per capita plateaued between 53 - 57 cases per 100, about 14 days
- Positivity rate continues at around 10%
- Testing demand low, has seen increased because of School-based rapid testing
- About 900,000 tests performed

COVID-19 Snapshot

- Rate of Asymptomatic patients about 16%
- Hospitalizations (7-day rolling avg) plateaued at 400 - 450/day
- 1 out of 3 hospitalized patients requiring ICU care
- Currently our TSA area COVID Hospitalization stable between 17-19%

COVID-19 Summary

- Positive Cases plateaued
- Hospitalizations remain stable without a significant increase
- Prevention is the key while vaccine is rolled out
- Need to encourage people to get tested

Dashboard


COVID-19 SITUATIONAL MONITORING
January 29, 2021
Positive Tests
368 New
112,652 Cumulative
COVID-19 Deaths
6 New
1681 Cumulative
Active
35,197
Recovered
75,188
Hospitalized
437
In ICU
165
COVID-19 Community Scorecard
Stage 2
Infection Rate 1
Testing 3
Investi-gations 4
Healthcare Readiness 1
At-Risk Population 4
Cumulative Cases
COVID-19 Positives Recoveries Deaths
100K
50K
0K
Apr 2020
Jul 2020
Oct 2020
Jan 2021
112652
75188
19325
17076
3232
2984
1352
1681
Case Disposition
Recovered 75,188
Active 35,197
COVID Related Death 1,681
Death Under Review 545
Non-COVID Death 41
112,652
All Cases
Zip Code Map
Bing
© 2021 Microsoft Corporation Terms
Click on Map Zip Codes to Filter Data
Cases by Race
100%
50%
0%
98.0%
1.4%
0.3%
0.2%
0.1%
White
African American
Asian
Native American
Pacific Islander
Cases by Gender
Male 53,244
Female 59,408
Cases by Ethnicity
Not Hispanic 8%
Hispanic 92%
Cases by Zip Code
Switch to Cities
79821 1,186
79835 1,760
79836 1,096
79838 1,355
79849 2,258
79853 617
79901 2,047
79902 2,399
79903 2,397
79904 3,250
79905 3,579
79907 7,711
Cases by Age Group
0-12 8,516
13-19 10,633
20-29 23,371
30-39 18,657
40-49 16,986
50-59 15,777
60-69 10,452
70-79 4,929
80-89 2,535
90-99 768
Clear Filters

COVID VARIANTS

- Three important Variants of Concern:
  - UK (B.1.1.7)
  - Southafrica (B1.351)
  - Brazil (P.1)
- Variants are more infectious
- NOT producing more severe disease
- Important mutations on Spike Protein

COVID VARIANTS

- Surveillance done by CDC and State labs
- To avoid infection: Mask (may use double), Distancing and Hygiene
- Vaccine still effective
- Travel Restrictions imposed at federal level

COVID VACCINE

- Two manufacturers approved and 1 more on Phase 3 Trials.
- Interval for second-dose slightly different but still effective if timing of second dose is longer that recommended
- Current vaccines still confer protection against new variants

COVID VACCINE

- Severe reactions (anaphylaxis) not common
- Vaccine important protection and indicated for persons with pre-existing medical conditions.
- Pregnant and breastfeeding mothers may receive the vaccine if at-risk

EL PASO CORONAVIRUS ANTIBODIES SURVEILLANCE SURVEY (ELPCASS)

RATIONALE and PURPOSE

- COVID-19 pandemic
- Limited assessment of infection
- Role of Asymptomatic
- Immune response

To find out how many El Pasoans have truly been infected with the coronavirus, the cause of COVID-19.

OBJECTIVES

- **Primary**

  Estimate the risk of SARS-CoV-2 infection in the population of El Paso

- **Secondary**

  Determine whether the prevalence of SARS-CoV-2 infection varies over time, and age, gender, Hispanic ethnicity, and industry/occupation.

POPULATION AND METHODS

- Cross-sectional weekly survey of randomly selected residents of El Paso
- Involves Two parts:
  1. Interview (pen/paper)
  2. A serologic LFA test (capillary blood sample)







TESTING


BIOMARKERS OF SARS-COV-2 INFECTION
IgM class Ab
IgG Class Ab
Viral shedding–Detectable by PCR or Ag test
-2
0
2
4
6
8
10
12
14
16
days
1
2
3
5
months
10
15
years

RESULTS

- 197 Interviews completed
- There were considerable variations in infection risk by age, Hispanic ethnicity, and education.
- Those with High School or less were 1.9 times more likely to be infected
- On Behaviors: 38% respondents left home ≥5 times
- Learned that Infection Fatality Ratio (IFR) is less than 1% while Case Fatality Ratio (CFR) was 2%

RESULTS

- As of December 2020, there were >90,000 reported cases and Based on results, there were approximately 155,000 infected
- Cumulative incidence of SARS-CoV-2 infection was 18.5% (36 positive test/197 tested)(95% CI: 9.6% 27.4%).
- Recent Infection (within 3 months) (IgM) 9.5%
- More than 3 months (IgG without IgM) 8.9%
- Adjustment for imperfect Se and Sp 17.6%≈ 18.5%
- One third of those positive results reported no symptoms

RESULTS

Behaviors



RESULTS FROM MORBIDITY DATA

- Hispanics found to have 2.9-times the risk of COVID-19 infection
- 21 times Excess Risk of death when people are older than 65 yrs of age and having Diabetes.
- Indirect relation between education level and risk of infection
- Found a direct relation between morbidity and poverty level

29

RESULTS


Age-Specific Rates of COVID-19/SARS-CoV-2 infections by age and gender, El Paso, Texas, March-December 2020
Cases per 1,000 population
180.0
160.0
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
0 to 4
5 to 9
10 to 14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Age Groups
Age-specific Rates Males
Age-Specific Rates Females

RESULTS


Reported cumulative incidence of COVID-19/SARS-CoV-2 infections by race/ethnicity, EL Paso, Texas, March-December, 2020
Cases or Infections per 1,000
120
100
80
60
40
20
0
0 to 4
5 to 9
10 to 14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Hispanics
Whites
Blacks

RESULTS

Table 2. Modification of the effect of diabetes mentioned in death certificate by age on the rate of mortality from COVID-29, El Paso, Texas 2020

Age Groups	Diabetes			
	No		Yes	
	Deaths	Population	Deaths	Population
Age				
20-64	267	450,328	243	33,896
MRR (95% CI)	1 (Referent)		12.1 (10.2, 14.4) *P* <0.0000001	
65+	181	55,848	1,109	49,327
MRR (95% CI)	5.5 (4.5, 6.6) *P* <0.0000001		37.9 (33.2, 43.3) *P* <0.0000001	

RERI (95% CI) For 65+ years with diabetes=37.9 – 12.1 – 5.5 + 1= 21.4 (17.9, 25.5).

El Paso United COVID-19 Transition Task Force Recommendations Recap

Recommendations Recap

5 Key Themes



28 Total Recommendations

- **Comprehensive Update Provided: 1.5.21**
  - **18 short term- COMPLETE**
  - **10 mid & long term – 7 COMPLETE + 3 Pending**

Communication #9: For accountability, to facilitate learning, and to document effort, the city/county, collaborating with public/private partners, should provide an **after-action report** that details COVID-19 communication activities (the implementation of this recommendation may extend beyond 18 months given the unpredictable nature of the current pandemic)

Preparedness #6: Develop a model for public health organization & strategic plan for **future public health emergencies**

Preparedness #7: Invest in **ongoing** population health and behavioral change research, resources, and interventions

2. Vaccination Update

Angela Mora

Vaccination Update

3rd. U.S. Vaccine - Johnson & Johnson/Janssen's COVID-19 vaccine

- If data from 3rd phase of clinical trials shows it works and is safe – application submission to FDA – then to ACIP
- Single dose
- Viral vector technology
- 45,000 clinical trial participants
- Age 18 to over 65

Vaccination Update Continued

- Preliminary findings - good immune response, sustained immunity
- Predictable side effects – fatigue, fever, headache, muscle aches
- Contractual 12 million doses by end of Feb 2021
- Effectiveness and efficacy –66%, 85% severe disease

- **Oxford-AstraZeneca** Covid-19 – Phase 3 of clinical trials in the US, potential EUA in early April

Clinical Trials for Children

Moderna – current >18 years

- Next down to 12 years of age
- Slow start - 3,000 goal, 800 enrolled/recruited
- Projected timeline – late 2021
- Ages 1-11 - last group
- Projected timeline – 2022

Clinical Trials for Children Continued

<u>Pfizer – current >16 years</u>

- Ages 12-15
- 2259 fully enrolled – closed
- Timeline - TBD

Vaccine Efficacy

- Efficacy = how well it works in clinical trials
- Following two doses of mRNA COVID-19 vaccine
- Pfizer-BioNTech: 95.0% [95% CI: 90.3%, 97.6%].
- Moderna: 94.1% [95% CI: 89.3%, 96.8%].
- Limited data are currently available regarding the efficacy of a single dose
- Johnson & Johnson 66%, 85% severe disease - following 1 dose

Second Dose Administration

- Moderna 28 days apart
- Pfizer 21 days apart
- CDC's recommendation 2nd dose as close to as possible
- 3 weeks, Pfizer-BioNTech
- 1 month, Moderna
- CDC's updated guidance – 1/21 - allows 2nd dose up to 6 weeks (42 days) after the first if it is not feasible
- CDC is not advocating for delay
- Data from clinical trials support this range

Vaccination Efforts in Cd. Juarez

- Pfizer vaccine – 2 dose
- Transported and secured by Mexican Army
- Phase 1 group 1a – public hospitals
- 2 week-long efforts
- Tight eligibility controls
- Dispensed by locals after eligibility confirmation by military
- Exhausted vaccines – total vaccinated 7081

Long Term Care Facilities Update

Administrating Source	Facility Type	Facility Type	Facility Type	Facility Type	Facility Type	Total Vaccinated
	SNF	ALF	Foster & Host Home	Hospice	Intellectual	As of 1/29
DPH	0	21	0	0	0	527 1st dose 340 2nd
DSHS	2	2	4	0	0	300 1st dose
Fire	0	0	47	0	0	241 1st dose
Pharmacy	15	14	0	0	0	TBD
Pending	4	4	32	20	14	(72 Pending)
Total	21	44	79	20	14	106 1068 1st dose 340 2nd dose

Next Steps

- Continue DSHS-City taskforce efforts
- Continue Fire deployment team
- Focus vaccinate first 165 facilities
- Vaccine resources
- Identify next golden age facilities/groups

Mission

Deliver exceptional services to support a high quality of life and place for our community

Values

Integrity, **R**espect, **E**xcellence, **A**ccountability, **P**eople

Vision

Develop a vibrant regional economy, safe and beautiful neighborhoods and exceptional recreational, cultural and educational opportunities powered by a high performing government

Thank you!